{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:06:48Z","timestamp":1788984408908,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-04056-1","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:30:50Z","timestamp":1772152250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Timing matters: radiation necrosis risk of antibody-drug conjugates (ADCs) combined with radiation therapy in breast cancer brain metastases: a systematic review and comparative meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Amirhessam","family":"Zare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Delbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mortezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hussain","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhang","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elshan","family":"Azarmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Ghalehtaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Tafakhori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"14","key":"4056_CR1","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 22(14):2865\u20132872","journal-title":"J Clin Oncol"},{"issue":"6","key":"4056_CR2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis M et al (2021) The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol 23(6):894\u2013904","journal-title":"Neuro Oncol"},{"issue":"6","key":"4056_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18(6):732\u2013742","journal-title":"Lancet Oncol"},{"issue":"1","key":"4056_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.adro.2019.07.012","volume":"5","author":"AB Barbour","year":"2020","unstructured":"Barbour AB et al (2020) Radiation therapy practice patterns for brain metastases in the united States in the stereotactic radiosurgery era. Adv Radiat Oncol 5(1):43\u201352","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"4056_CR5","doi-asserted-by":"publisher","first-page":"101402","DOI":"10.1016\/j.adro.2023.101402","volume":"9","author":"C Ladbury","year":"2024","unstructured":"Ladbury C et al (2024) Stereotactic radiosurgery in the management of brain metastases: A Case-Based radiosurgery society practice guideline. Adv Radiat Oncol 9(3):101402","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"4056_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-016-3828-6","volume":"157","author":"W Jacot","year":"2016","unstructured":"Jacot W et al (2016) Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat 157(2):307\u2013318","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"4056_CR7","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1158\/1078-0432.CCR-18-2851","volume":"25","author":"PK Stumpf","year":"2019","unstructured":"Stumpf PK et al (2019) Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of Aquaporin-4. Clin Cancer Res 25(13):3946\u20133953","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4056_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/neuonc\/not329","volume":"16","author":"JA Carlson","year":"2014","unstructured":"Carlson JA et al (2014) Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol 16(7):1006\u20131009","journal-title":"Neuro Oncol"},{"key":"4056_CR9","doi-asserted-by":"publisher","first-page":"110461","DOI":"10.1016\/j.radonc.2024.110461","volume":"199","author":"SJ Chun","year":"2024","unstructured":"Chun SJ et al (2024) Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery. Radiother Oncol 199:110461","journal-title":"Radiother Oncol"},{"key":"4056_CR10","doi-asserted-by":"publisher","first-page":"104270","DOI":"10.1016\/j.critrevonc.2024.104270","volume":"195","author":"S Natangelo","year":"2024","unstructured":"Natangelo S et al (2024) Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates. Crit Rev Oncol Hematol 195:104270","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"4056_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","volume":"168","author":"Y Koide","year":"2024","unstructured":"Koide Y et al (2024) Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study. J Neurooncol 168(3):415\u2013423","journal-title":"J Neurooncol"},{"issue":"12","key":"4056_CR12","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow ES et al (2023) Symptomatic necrosis with Antibody-Drug conjugates and concurrent stereotactic radiotherapy for brain metastases. JAMA Oncol 9(12):1729\u20131733","journal-title":"JAMA Oncol"},{"key":"4056_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"4056_CR14","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"issue":"1","key":"4056_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12(1):55\u201361","journal-title":"Res Synth Methods"},{"key":"4056_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"4056_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-016-2265-z","volume":"131","author":"A Geraud","year":"2017","unstructured":"Geraud A et al (2017) Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer. J Neurooncol 131(1):69\u201372","journal-title":"J Neurooncol"},{"issue":"1","key":"4056_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12885-021-07971-w","volume":"21","author":"MN Mills","year":"2021","unstructured":"Mills MN et al (2021) Trastuzumab emtansine (T-DM1) and stereotactic radiation in the management of HER2\u2009+\u2009breast cancer brain metastases. BMC Cancer 21(1):223","journal-title":"BMC Cancer"},{"issue":"1","key":"4056_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-022-04055-y","volume":"159","author":"B Id Said","year":"2022","unstructured":"Id Said B et al (2022) Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2\u2009+\u2009breast cancer. J Neurooncol 159(1):177\u2013183","journal-title":"J Neurooncol"},{"issue":"1","key":"4056_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41523-024-00711-w","volume":"10","author":"VM Khatri","year":"2024","unstructured":"Khatri VM et al (2024) Multi-institutional report of trastuzumab Deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases. NPJ Breast Cancer 10(1):100","journal-title":"NPJ Breast Cancer"},{"key":"4056_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2019.11.001","volume":"125","author":"D Pasquier","year":"2020","unstructured":"Pasquier D et al (2020) Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. Eur J Cancer 125:22\u201330","journal-title":"Eur J Cancer"},{"key":"4056_CR22","doi-asserted-by":"publisher","first-page":"175883592412922","DOI":"10.1177\/17588359241292266","volume":"16","author":"S Pan","year":"2024","unstructured":"Pan S et al (2024) Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases. Ther Adv Med Oncol 16:17588359241292266","journal-title":"Ther Adv Med Oncol"},{"key":"4056_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153682","author":"R Tonse","year":"2021","unstructured":"Tonse R et al (2021) Integration of systemic therapy and stereotactic radiosurgery for brain metastases. Cancers (Basel) 13(15):3682. https:\/\/doi.org\/10.3390\/cancers13153682","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4056_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11940-016-0416-3","volume":"18","author":"Z Aly","year":"2016","unstructured":"Aly Z, Peereboom DM (2016) Combination of radiotherapy and targeted agents in brain metastasis: an update. Curr Treat Options Neurol 18(7):32","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"4056_CR25","first-page":"45","volume":"12","author":"PE Valk","year":"1991","unstructured":"Valk PE, Dillon WP (1991) Radiation injury of the brain. AJNR Am J Neuroradiol 12(1):45\u201362","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"4056_CR26","first-page":"437","volume":"71","author":"K Wang","year":"2021","unstructured":"Wang K, Tepper JE (2021) Radiation therapy-associated toxicity: etiology, management, and prevention. CA Cancer J Clin 71(5):437\u2013454","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4056_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-025-01013-1","volume":"22","author":"A Mansouri","year":"2025","unstructured":"Mansouri A et al (2025) Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care. Nat Rev Clin Oncol 22(5):327\u2013347","journal-title":"Nat Rev Clin Oncol"},{"issue":"12 Suppl 2","key":"4056_CR28","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1093\/neuonc\/noad188","volume":"26","author":"ZS Mayo","year":"2024","unstructured":"Mayo ZS et al (2024) The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases. Neuro Oncol 26(12 Suppl 2):S56\u2013s65","journal-title":"Neuro Oncol"},{"issue":"2","key":"4056_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/jon.13080","volume":"33","author":"A Aseel","year":"2023","unstructured":"Aseel A, McCarthy P, Mohammed A (2023) Brain magnetic resonance spectroscopy to differentiate recurrent neoplasm from radiation necrosis: a systematic review and meta-analysis. J Neuroimaging 33(2):189\u2013201","journal-title":"J Neuroimaging"},{"issue":"1","key":"4056_CR30","doi-asserted-by":"publisher","first-page":"e0141438","DOI":"10.1371\/journal.pone.0141438","volume":"11","author":"MT Chuang","year":"2016","unstructured":"Chuang MT et al (2016) Differentiating Radiation-Induced necrosis from recurrent brain tumor using MR perfusion and spectroscopy: A Meta-Analysis. PLoS ONE 11(1):e0141438","journal-title":"PLoS ONE"},{"issue":"1","key":"4056_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-023-04528-8","volume":"166","author":"R Dagher","year":"2024","unstructured":"Dagher R et al (2024) Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in differentiating between brain tumor progression versus pseudoprogression and radionecrosis. J Neurooncol 166(1):1\u201315","journal-title":"J Neurooncol"},{"issue":"4","key":"4056_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V et al (2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(4):265\u2013282","journal-title":"Pract Radiat Oncol"},{"issue":"11","key":"4056_CR33","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E et al (2021) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32(11):1332\u20131347","journal-title":"Ann Oncol"},{"issue":"4","key":"4056_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00066-024-02202-0","volume":"200","author":"KJ Borm","year":"2024","unstructured":"Borm KJ et al (2024) DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer. Strahlenther Onkol 200(4):259\u2013275","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"4056_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07889-3","volume":"21","author":"M Khan","year":"2021","unstructured":"Khan M et al (2021) Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis. BMC Cancer 21(1):167","journal-title":"BMC Cancer"},{"key":"4056_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091649","author":"D Krug","year":"2024","unstructured":"Krug D et al (2024) The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy-a retrospective multi-center cohort study. Cancers (Basel) 16(9):1649. https:\/\/doi.org\/10.3390\/cancers16091649","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4056_CR37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3171\/2010.8.JNS10461","volume":"114","author":"D Kondziolka","year":"2011","unstructured":"Kondziolka D et al (2011) Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical Article. J Neurosurg 114(3):792\u2013800","journal-title":"J Neurosurg"},{"issue":"4","key":"4056_CR38","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.rpor.2020.04.007","volume":"25","author":"S McClelland","year":"2020","unstructured":"McClelland S 3 et al (2020) Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol. Rep Pract Oncol Radiother 25(4):500\u2013506","journal-title":"Rep Pract Oncol Radiother"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-04056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-04056-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-04056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:30:51Z","timestamp":1772152251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-04056-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4056"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-04056-1","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}